Ovid Therapeutics (OVID) Q4 2025 earnings summary

Executive summary

• OV329, a next-generation GABA-AT inhibitor, advanced with strong safety and tolerability at up to 7 mg, supporting expansion into infantile spasms and tuberous sclerosis complex seizures.

• OV4071, a first-in-class oral KCC2 direct activator, received regulatory clearance for Phase 1 trials in Australia, targeting psychosis and neurodegenerative conditions.

• Pipeline expansion enabled by $60M PIPE/private placement financing and potential $53M–$53.9M from Series A warrant exercises, extending cash runway into late 2028 or 2029.

• New clinical programs launched for OV329 in pediatric epilepsy indications, including infantile spasms and TSC.

• OV4071 and OV350 advanced as KCC2 activators, with OV350 showing first clinical validation of direct KCC2 activation in humans.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $90.4M as of December 31, 2025, up from $53.1M at year-end 2024.

• $60M PIPE/private placement financing announced, with additional potential proceeds from warrant exercises.

• Revenue was $0.7M for Q4 2025 and $7.3M for FY 2025, including a one-time $7.0M payment.

• Net income for Q4 2025 was $9.7M, driven by a $21.0M gain on long-term equity investment adjustment.

• Net loss for FY 2025 was $17.4M, improved from $26.4M in FY 2024.

Outlook and guidance

• Phase II randomized placebo-controlled trial for OV329 in focal onset seizures to begin in Q2 2026.

• Proof-of-concept studies for OV329 in TSC seizures and IS planned for Q4 2026 and 2027.

• OV4071 Phase I study to initiate in Q2 2026, followed by a ketamine challenge study and proof-of-concept trials.

• Multiple clinical and regulatory milestones anticipated through 2027.

• Additional KCC2 activator candidates in discovery, with more details to be shared at an R&D event in April.